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Mario Raviglione, World Health Organiza-
tion (WHO), described  the epidemiology of global
tuberculosis (TB) using surveillance data avail-
able to WHO from 212 countries and data from a
recent survey of antituberculosis drug resistance
in 32 countries. Countries were categorized
according to the degree of TB directly observed
treatment strategy (DOTS) implementation.
Performance of national TB programs was
assessed by using treatment outcome indicators.
In 1996, 3.8 million TB cases (887,731 from areas
with DOTS) were reported to WHO. In
developing countries, the bulk of TB cases are
found in all age groups of native-born popula-
tions, while in many industrialized countries a
large proportion of TB cases are in foreign-born
residents. In countries of the former Soviet
Union, TB cases and deaths have doubled in just
a few years. Drug resistance and HIV infection
related to TB are found only in limited foci.
Acquired multidrug-resistant TB (MDRTB) was
present in 27% to 54% of culture-positive TB
cases from the Baltic countries and Russia. The
effect of the HIV epidemic on TB has been major
in Africa, where HIV seroprevalence among TB
cases is 50% to 70% and TB case notifications
have at times tripled. Countries with inadequate
TB control are particularly exposed to the
consequences of both epidemics. In Southeast
Asia, cases are increasing, and MDRTB is
common in Thailand, China, and Vietnam.
One hundred eighty-one countries and
territories (97% of the global population) have
reported on the status of DOTS to WHO. Of these,
96 implemented DOTS (63 countrywide). Ap-
proximately 32% of the global population lives in
areas where DOTS is available. Twenty countries
have adopted DOTS since the 1996 survey, and
an additional 9% of the global population were
benefitting from it. However, most of these new
countries had small populations; DOTS was only
slowly implemented in countries with high TB
prevalence. In areas that used DOTS, treatment
outcome evaluation remains high (94%), and
treatment success rose from 76% in 1994 to 78%
in 1995. In areas that did not use DOTS, 45% of
reported TB cases were not evaluated, and
treatment success remained low (45%). Among
the 22 countries with the highest TB prevalence,
six showed progress in DOTS implementation,
seven showed little progress, and nine did not
implement DOTS. In summary, TB remains an
important public health problem in many areas of
the world where DOTS has not been imple-
mented. Because treatment outcomes were
better in countries where DOTS has been used,
the strategy needs to be expanded rapidly and
new tools to facilitate its implementation need to
be developed.
Barry Bloom, Howard Hughes Medical
Institute, described advances in TB vaccine
development. The available bacillus Calmette-
Guerin (BCG) vaccine has a demonstrated
efficacy ranging from no protection to 80%
protection. Most recently, a meta analysis
estimated that the overall efficacy of BCG is 50%.
Because of case reports of disseminated BCG
infection, this vaccine is contraindicated in
immunocompromised persons, and safer and
more efficacious vaccines are clearly needed.
Identifying such new vaccines for use in humans
will take several years. However, recent
advances in this area provide optimism. Recent
research activities have improved our under-
standing of the immunologic response to
Mycobacterium tuberculosis and identified major
protein antigens of M. tuberculosis and recombi-
nant BCG forms that overexpress protective
antigens. Additionally, avirulent auxotrophic
mutants of both BCG and M. tuberculosis have
been used in animal models. The recent
sequencing of the M. tuberculosis genome has
presented additional opportunities to identify
virulence factors that could be deleted and other
target sites that could be genetically engineered.
DNA constituents can also be used to develop
candidate vaccines. In animal studies, subunit
vaccines consisting of pooled mycobacterial culture-
filtrate proteins have been protective. Auxotrophic
mutants may also prove useful in immuno-
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compromised patients, as may recombinant BCG
vaccines that secrete host-specific cytokines.
Clearly, a major national effort is required for TB
vaccine development, recommendations on policies
and priorities, and cooperation between the
government and private sector in these efforts.
Christopher Murray, Harvard School of
Public Health, described a mathematical model
developed to forecast the future impact of
improvements in TB prevention and control.
Specifically, this model projected the number of
TB cases and deaths averted through the year
2050. Different scenarios were simulated to
project the effect of adding TB vaccines to
existing interventions. Six specific scenarios
assessed the effect of vaccines (with efficacy
levels of 20%, 50%, and 80%) to protect from M.
tuberculosis infection, as well as the effect of
vaccines of the same levels of efficacy to protect
latently infected persons from “breakdown” to
active TB. Although a TB infection vaccine with
20% efficacy would prevent more than 30 million
TB cases, the best protection is obtained from a
TB breakdown vaccine with 80% efficacy, which
would prevent almost 130 million TB cases. The
breakdown vaccine could be used in the large
number of persons with latent M. tuberculosis
infection, now estimated at almost one third of
the world’s population. Such anticipated gains
justify the effort to develop better TB vaccines.
Denise Garrett, Centers for Disease Control
and Prevention, presented the findings of recent
tuberculin skin test studies regarding the risk for
TB among health-care workers in Thailand and
Brazil. In Thailand, 35% of 911 health-care
workers had a positive test at the 15-mm cutoff,
while 69% were positive at the 10-mm cutoff.
BCG scar was associated with positive skin test
reaction at the lower cutoff value, but not at the
15-mm cutoff. Additionally, tuberculin skin test
reactivity correlated with more than 1 year’s
employment as a health-care worker, and with
occasional or frequent patient contact. In Brazil,
48% of 524 health-care workers had a reaction of
10 mm, while 26% had a reaction of  15 mm. As in
Thailand, BCG scar correlated only with  10-mm
skin test reactivity but not with  15-mm. Workers
with occasional or frequent patient contact were
also more likely to have a positive tuberculin test.
Factors that appear to contribute to the risk for
TB in these workers include delays in the
diagnosis of TB, inadequate isolation practices,
and lack of personal protection during high-risk
procedures. Important measures to reduce the
risk for TB in these settings include increasing
the awareness and training of health-care
workers about the risk for TB, improving the
ability to establish the diagnosis of TB by smear
microscopy, reducing the need for hospitalization
of TB patients, considering the establishment of
chest clinics at separate times or in separate
areas, and improving ventilation by keeping
windows open. Laboratories should contain all
needed safety features.